Hyphens Pharma International Limited (SGX:1J5)

Singapore flag Singapore · Delayed Price · Currency is SGD
0.3400
-0.0050 (-1.45%)
At close: Feb 6, 2026
Market Cap105.02M +17.2%
Revenue (ttm)185.32M -5.2%
Net Income6.46M -38.0%
EPS0.02 -38.8%
Shares Out308.87M
PE Ratio16.62
Forward PE9.42
Dividend0.02 (4.41%)
Ex-Dividend DateMay 7, 2025
Volume508,000
Average Volume184,900
Open0.3450
Previous Close0.3450
Day's Range0.3400 - 0.3500
52-Week Range0.2600 - 0.3950
Beta0.11
RSI44.86
Earnings DateFeb 26, 2026

About SGXC:1J5

Hyphens Pharma International Limited, together with its subsidiaries, operates as a specialty pharmaceutical and consumer healthcare company primarily in Singapore, Vietnam, Malaysia, and internationally. It operates through Specialty pharma principals; Proprietary brands; and Medical hypermart and digital segments. The Specialty Pharma Principals segment markets and sells specialty pharmaceutical products, including contrast media products, Stérimar nasal sprays, Bausch+Lomb eye drops, Vivomixx, Fenosup Lidose, and Piascledine products through... [Read more]

Industry Pharmaceutical Preparations
Founded 1998
Employees 474
Stock Exchange Singapore Exchange - Catalist
Ticker Symbol 1J5
Full Company Profile

Financial Performance

In 2024, SGXC:1J5's revenue was 195.42 million, an increase of 14.55% compared to the previous year's 170.60 million. Earnings were 10.19 million, an increase of 18.98%.

Financial Statements